Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World

NCT00703924 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

92

Enrollment

FED

Sponsor class

Conditions

Cutaneous Leishmaniasis

Interventions

DRUG: WR 279,396
DRUG: Placebo

Sponsor

U.S. Army Medical Research and Development Command

Collaborators

[object Object]